Keith Kellum, MD
Ophthalmology · Houma, LANPI 1225036023
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 356 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,690, 2.7 times the $999 reported in 2019. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $28.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alcon$2K
- Ivantis, Inc$808
- Sight Sciences, Inc.$738
- Lumenis BE Inc$663
- Oyster Point Pharma, Inc.$484
- plus $3K from 25 others
Across 6 payments — averaging $2079.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$12K
What the payments were for
- Speaking & faculty fees$260%
- Food & beverage$10,13499%
- Gifts$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 128 | $2,307 |
| Alcon | 64 | $2,059 |
| Ivantis, Inc | 21 | $808 |
| Sight Sciences, Inc. | 10 | $738 |
| Lumenis BE Inc | 1 | $663 |
| Oyster Point Pharma, Inc. | 18 | $484 |
| Glaukos Corporation | 5 | $321 |
| Bausch & Lomb Americas Inc. | 13 | $284 |
| Sun Pharmaceutical Industries Inc. | 14 | $261 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $250 |
| NEW World Medical,inc. | 5 | $232 |
| Dompe US, Inc. | 6 | $184 |
| Amgen(2 entities) | 9 | $180 |
| Regeneron Healthcare Solutions, Inc. | 2 | $156 |
| Harrow Eye, LLC | 6 | $154 |
| Iridex Corporation | 1 | $150 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $122 |
| Apellis Pharmaceuticals, Inc. | 2 | $121 |
| Aerie Pharmaceuticals, Inc. | 6 | $94 |
| Carl Zeiss Meditec USA, Inc. | 1 | $94 |
| Rxsight Inc | 5 | $93 |
| Biotissue Holdings Inc. | 5 | $83 |
| Kala Pharmaceuticals, Inc. | 4 | $76 |
| Genentech USA, Inc. | 3 | $54 |
| Novartis | 3 | $47 |
| Tarsus Pharmaceuticals, Inc. | 3 | $46 |
| Mallinckrodt Hospital Products Inc. | 2 | $44 |
| Rayner Intraocular Lenses Limited | 1 | $32 |
| Ocular Therapeutix, Inc. | 2 | $30 |
| Coherus Oncology, Inc. | 1 | $25 |
| Johnson & Johnson Vision Care, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- M22$663
- Hydrus Microstent$660
- OMNI(R) SURGICAL SYSTEM (US)$280
- DURYSTA$247
- IACCESS$151
- iStent inject W$151
- TearCare SmartLid$150
- TEARCARE(TM) (2.2) SYSTEM KIT$150
- TEARCARE SYSTEM$148
- SION SURGICAL INSTRUMENT$137
- LenSx$133
- ReSTOR$129
- XEN$125
- EYLEA$125
How this compares
$10,205 in reported general payments places this provider in the 90th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 153 | $148,447 |
| LumiganBimatoprost | 445 | $145,486 |
| XiidraLifitegrast | 69 | $49,064 |
| TyrvayaVarenicline Tartrate | 32 | $26,753 |
| RhopressaNetarsudil Mesylate | 60 | $25,324 |
| RocklatanNetarsudil Mesylat/Latanoprost | 67 | $25,183 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 88 | $22,393 |
| Cyclosporine | 62 | $22,206 |
| Prednisolone Acetate | 396 | $18,125 |
| Travoprost | 119 | $13,489 |
| CombiganBrimonidine Tartrate/Timolol | 45 | $12,310 |
| VyzultaLatanoprostene Bunod | 21 | $10,846 |
| Alphagan PBrimonidine Tartrate | 30 | $10,437 |
| Brimonidine Tartrate | 276 | $9,028 |
| Ketorolac Tromethamine | 373 | $8,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $2,307 | $316,680673 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $284 | $59,90990 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $94 | $50,507127 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $484 | $26,75332 claims |
| AlconSimbrinza | $2,059 | $22,39388 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $250 | $2,10515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Houma
- Arthur DelahoussayeHouma$26K
- Aravinda RaoHouma$8K
- Blake WilliamsonBaton Rouge$443K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
- Wyche ColemanShreveport$35K
- Peter KastlNew Orleans$32K
- Bryan VekoviusShreveport$29K
- Christopher ShelbyShreveport$27K
- Michael RedmondAlexandria$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.